Kalorama Announces List of "Proteomics Pioneers"
NEW YORK, Nov. 3, 2014 /PRNewswire-USNewswire/ -- Several companies are well-ahead in the race for novel or emerging proteomic biomarkers that will determine the future of testing and drug development, according to Kalorama Information. Proteomics is the study of proteins, including the study of the structure and function of proteins, and proteomics technologies are important tools for research focusing on proteins. The healthcare research publisher has chosen 15 companies that are marketing or developing proteomic biomarkers of interests. The firm conducted an extensive study of the market in 2013.
According to Kalorama, researchers who are studying biological processes such as metabolic, signaling, or other pathways do so by studying proteins. Proteins are the active biological molecules expressed by an organism's genome and have many different functions, and are involved in most cellular processes. Researchers studying the immune system or the inflammatory response study proteins such as antibodies and cytokines, and those proteins expressed by immune cells.
"Most drug targets and many of the newest, most effective drugs are proteins as well," said Bruce Carlson, Publisher of Kalorama Information. "The companies in this list, and it is by no means a complete list, will be companies to observe over the next five years."
Kalorama lists the following companies among the proteomic pioneers in its report:
| Company |
Novel/Emerging Biomarker |
Status |
| AmniSure International LLC/Qiagen |
Placental Alpha Microglobulin-1 (PAMG-1) protein in amniotic fluid |
On the market |
| Augurex Life Sciences Corp. |
14-3-3η, a protein biomarker of arthritis |
In development |
| Avant Diagnostics, Inc. |
OvaDx, a microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. This new test detects approximately 100 proteomics biomarkers |
In development |
| BioPorto Diagnostics A/S |
NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2, siderocalin) is a biomarker for diagnosing acute kidney injury |
On the market; Licensed to major IVD companies |
| CardioGenics Holdings, Inc. |
Heart Failure Risk Stratification (HFRS) test |
In development |
| diaDexus Inc.
|
PLAC Test for Lp-PLA2 (lipoprotein-associated phospholipase A2); Lp-PLA2 is a vascular-specific inflammatory enzyme implicated in the formation of rupture-prone plaque
|
On the market
|
| Diagenics SE |
DIACORDON is a blood test that detects Glycogen-Phosphorylase Isoenzyme BB (GPBB), an enzyme found in heart tissue that is released into the blood when myocardial ischemia (heart attack) occurs |
On the market |
| Genalyte, Inc. |
Tumor Antigen-Associated (TAA) Autoantibody panel |
In development |
| Immunexpress Group |
SeptiCyte technology, comprised of over 300 proprietary biomarkers; SeptiCyte Triage, a multiplex gene expression assay to differentiate sepsis from other forms of inflammation |
In development with Biocartis; Debiopharm |
| OncoHealth Corporation |
Proprietary biomarkers for direct detection of HPV E6E7 oncoproteins; Has pan-antibody to detect E6 produced by all high-risk HPV strains and a pan-antibody for E7. Multiple products. Some tests CE marked; All for research use only in US. |
Multiple tests; Some CE marked; All RUO in US |
| Protagen AG |
Proprietary platform utilizes hPEX® (human antigen library) and SeroTag® (process for biomarker development). Biomarker focus is on autoimmune diseases |
In development |
| Sera Prognostics, Inc. |
Using mass spectrometry based proteomics technologies to identify biomarkers and develop blood tests to predict the risk of preterm birth, preeclampsia, and other complications of pregnancy; PreTRM™ test - to identify women at risk of preterm birth early in their pregnancy (between 17 and 28 weeks of gestation), before the onset of symptoms |
In development |
| SQi Diagnostics Inc. |
Crohn's disease/IBD Ig_plex™ 9-Plex |
In development |
| Venaxis, Inc. (Formerly Aspen BioPharma, Inc.) |
APPY1, a blood-based test to aid in the identification of patients at risk of developing acute appendicitis; Detects multiple biomarkers - the MRP 8/14 biomarker (calprotectin, a proprietary marker patented by ApsenBio Pharma), C-reactive protein (CRP), and white blood cell (WBC) count. MRP 8/14 and CRP are detected using immunoassay technology. |
In development |
|
Wako Diagnostics/Wako Life Sciences, Inc. |
Lectin-reactive alpha-fetoprotein (AFP-L3) and des-gamma-carboxy prothrombin (DCP) – two tumor markers for hepatocellular carcinoma (HCC) |
On the market |
Kalorama suggests that there are scores of companies that will develop novel biomarkers that researchers need for new drug development. Proteomics technologies and products are widely sold to researchers in the academic, pharmaceutical or biopharmaceutical, and diagnostic markets. Alternatively, a novel biomarker (or panel of novel biomarkers) may be useful for early detection of a disease such as cancer, predicting what therapy should be used; this type of use would be considered personalized medicine.
Kalorama's full report contains market sizing estimates for segments of proteomics and technologies used in proteomics research. The report can be found at http://www.kaloramainformation.com/Proteomics-Mass-Spectrometry-8359865/
About Kalorama Information -- Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog.
Contact:
Bruce Carlson
(212) 807-2622
[email protected]
Logo - http://photos.prnewswire.com/prnh/20140801/132634
SOURCE Kalorama Information
Share this article